18F-FAPI PET in the Diagnosis of Liver Fibrosis

Qingdao University

Status: Unknown

Conditions: FAP; Liver Fibrosis; Positron Emission Tomography

Treatments: Diagnostic Test: 18F-FAPI

Study type: Observational

Funder types: Other

Identifiers

NCT05262647

QYFYWZLL26714

Details and patient eligibility

About

It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis. The point of the clinical trial is to evaluate the novel biomaker 18F-FAPI-04 by PET-CT scan in the evaluation of the hepatic fibrosis.

Full description

Participants are with clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and congestive hepatopathy etc.

Participants are without liver tumor and other liver disease besides liver fibrosis Participants has no history of malignant tumors Participants agree to performe FAPI PET and liver biopsy

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and congestive hepatopathy etc.
• Without liver tumor and other liver disease besides liver fibrosis
• No history of malignant tumors
• Agree to performe FAPI PET and liver biopsy

Exclusion criteria

• Pregnancy
• With anti-hepatic fibrosis treatment in 6 months
• With contraindications to percutaneous liver biopsy,for such as uncooperative patient, severe coagulopathy, extrahepatic biliary obstruction,etc.